History of Bretisilocin in Timeline
Bretisilocin, also known as GM-2505 or 5-fluoro-N-methyl-N-ethyltryptamine, is a serotonergic psychedelic tryptamine analogue under development as a treatment for major depressive disorder. It's a 5-fluorinated derivative of methylethyltryptamine (MET) and an analogue of dimethyltryptamine (DMT). The administration route for Bretisilocin is intravenous infusion.
2022: First Description in Literature
In 2022, Bretisilocin was first described in the scientific literature.
June 2025: Phase 2 Clinical Trials
In June 2025, Bretisilocin is in phase 2 clinical trials for the treatment of major depressive disorder, and a phase 2a trial has been completed, with the efficacy and safety data released.
August 2025: Acquisition by AbbVie
In August 2025, AbbVie acquired Bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion.
Trending
7 months ago Court Rules Trump Can Restrict Associated Press Access: Implications for Journalism
28 days ago Dominion Energy: AI Upside, Offshore Wind Progress, and a New 1-Year High.
1 month ago Shane Gillis Announces Massive 2026 Homecoming Show at Lincoln Financial Field
2 months ago Beyoncé and Jay-Z Spotted in Qatar: Headscarf Sparks Debate.
5 months ago USDA invests $152M in Iowa rural communities, announced by Secretary Rollins at Iowa State Fair.
9 months ago Suriname faces discrimination concerns, Dutch appeal, and a company rebranding for exploration.
Popular
Stranger Things created by the Duffer Brothers is a popular...
XXXTentacion born Jahseh Dwayne Ricardo Onfroy was a controversial yet...
The Kennedy Center Honors are annual awards recognizing individuals and...
Turning Point USA TPUSA is an American nonprofit organization founded...
Bernie Sanders is a prominent American politician currently serving as...
Candace Owens is an American conservative political commentator and author...